Shield Therapeutics (LSE:STX) reported a substantial increase in Q2 2025 net revenues for its ACCRUFeR® product, which doubled from Q1 to $12.8 million. This growth was driven by higher prescription volumes and an improved average net selling price. The company’s cash position was strengthened through milestone payments from international partners, supporting its goal of achieving positive cash flow by the end of 2025. The strong uptake of ACCRUFeR® highlights its potential to become the leading oral iron therapy for patients with iron deficiency, enhancing Shield’s strategic market presence.
Despite robust revenue growth and favorable corporate developments, Shield Therapeutics faces financial challenges. Technical indicators show upward momentum but suggest possible volatility ahead, while valuation metrics remain a concern.
More about Shield Therapeutics
Shield Therapeutics plc is a specialty pharmaceutical company at the commercial stage, focused on treating iron deficiency with its innovative ACCRUFeR®/FeRACCRU® (ferric maltol). This therapy is the first and only FDA-approved oral iron treatment for iron deficiency and anemia, featuring a unique absorption mechanism. Shield holds exclusive licensing agreements for ACCRUFeR® across key global markets including the U.S., Europe, China, and Japan.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply